|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||1.5500 - 1.6160|
|52 Week Range||0.9000 - 3.6500|
|Beta (3Y Monthly)||4.80|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||8.00|
ARVO is the largest and most respected eye and vision research organization in the world. Mannin delegates will be meeting with key partners, researchers, and vendors to further its business development and R&D goals as it relates to progressing the MAN-01 program for treatment of glaucoma into the clinic for its Phase I trial. QBioMed has the global rights to all Mannin Tie2 assets and is working with Mannin Research to accelerate the development and commercialization of MAN-01 and other portfolio assets.
Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today the discovery of two novel biomarkers for pediatric nonverbal autism, identified in a subset of children with Autism Spectrum Disorder (ASD). This marks the first time a company has been able to identify biomarkers that hold the potential to stratify this subset of children.
New York, New York--(Newsfile Corp. - March 27, 2019) - "In the near-term, Q BioMed Inc. (OTCQB: QBIO) has multiple shots on goal with respect to market share, revenue and profit in the multi-billion dollar glaucoma market," says former Piper Jaffray analyst and mutual fund manager Rob Goldman, who now heads up Goldman Small Cap Research.Just weeks after the company announced that it had exercised its option to exclusively license GDF15, a diagnostic marker ...
NEW YORK, NY / ACCESSWIRE / March 21, 2019 / Q BioMed (QBIO) and its key technology partners are set to initiate development of an industry-changing diagnostic kit for monitoring glaucoma severity and progression. Pending FDA clearance, which could come sooner than many biotech investors might expect, this kit offers the potential to improve the quality of life for glaucoma sufferers by helping preserve visual function in glaucoma patients through accurate monitoring of disease progression. Based on the novel GDF15 biomarker, this kit's core, platform technology enables more effective measurement and management of glaucoma progression and patient treatment than any current monitoring or therapeutic approaches---a tremendous advantage.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, announced today that its technology partner Mannin Research Inc. has entered into a research collaboration with the Biointerfaces Institute at McMaster University in Ontario, Canada to develop a GDF15 biomarker diagnostic kit for monitoring glaucoma severity and progression. This enabling technology will act as a companion diagnostic to the MAN-01 small molecule therapeutic with a novel mechanism of action for the treatment of Primary Open-Angle Glaucoma.
OTCQX and OTCQB Companies Featured at 2019 ROTH Conference NEW YORK , March 13, 2019 /PRNewswire/ -- OTC Markets Group Inc . (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, ...
BALTIMORE, Maryland, March 12, 2019 /PRNewswire/ -- Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a new Company Spotlight article on high profile biomedical company Q Biomed Inc. (QBIO). To view this article, along with disclosures and disclaimers, or to download them in their entirety, please visit http://www.goldmanresearch.com. Yesterday, Q Bio announced that it exercised its option to exclusively license "GDF15", a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. In our view, this is a landmark event not just for Q Bio but for current and future sufferers of glaucoma, whose numbers could reach 80-100 million by 2020, according to market research sources.
Q BioMed Inc. (QBIO), a commercial stage biotechnology acceleration development company, is pleased to announce it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity of glaucoma using this biomarker will aid in treatment decisions for patients diagnosed with, and being treated for, glaucoma. Currently, no single examination or diagnostic test is able to accurately predict disease progression.
NEW YORK, NY / ACCESSWIRE / March 7, 2019 / Q BioMed (QBIO), has been getting attention from biotech investors and pharma industry publications for its "upside down" biotech business model. Q BioMed's CEO, Denis Corin, has toldthe investment community that he had no interest in building his firm the same way that had caused so many biotechs to fail. "After my years of experience watching biotech firms collapse under their own weight of debt and financing structures, we set out to put together a biotechnology firm that is very specifically focused on the capital structure of the company, the business operations, being well funded and filled with innovative technologies that we think are under-serviced and under-valued.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, today announced that in the February issue of DDNews, journalists conducted an interview with Q BioMed CEO Dennis Corin, focused on the mechanism of action, development path, and market opportunities of QBM-001 which is being developed to help treat rare pediatric non-verbal autism spectrum disorder. DDNews is a respected monthly newspaper dedicated to the news of technology and business in the pharmaceutical and biotechnology industries.
NEW YORK, Feb. 22, 2019 -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announces multiple interviews with the company’s CEO, Denis Corin, and the Q.
NEW YORK, NY / ACCESSWIRE / February 8, 2019 / Q BioMed (QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally. The illness often remains undetected long after significant vision loss has already occurred and in the most common form, known as open-angle glaucoma, there are usually no symptoms and no pain associated with the increase in intraocular pressure that leads to optic nerve damage. A 2014 study published in Ophthalmology, the journal of the American Academy of Ophthalmology, by Y.C. Tham et al. of the Singapore Eye Research Institute projected that the number of people worldwide, aged 40 to 80 years, with glaucoma would grow from an estimated 64 million in 2013 to 76 million in 2020 and nearly 112 million people by the year 2040.
NEW YORK, Feb. 7, 2019 /PRNewswire/ -- Q BioMed Inc. (QBIO), is providing this response at the request of the OTC markets inquiry into recent expanded investor awareness activities undertaken by the Company. Expecting several corporate developments and news events, the Company's investor relations consulting firm engaged a new sub-contracted service provider on January 1, 2019, to assist in presenting the Company to a broader audience. The third-party service provider, Platinum Vlll Investment and Media LLC, has several outlets that it contracts with to provide visibility to its clients, including the Company, using its various subscriber bases.
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- www.FinancialBuzz.com, a respected source in the financial news media space located on Wall Street, today announces an exclusive video interview with Q Biomed Inc. (QBIO) Chairman and CEO, Denis Corin from the floor of the NASDAQ MarketSite at Times Square New York City. Mr. Corin shares with us his vision of Company's growth and why he believes 2019 and beyond are essential years for Q BioMed Inc. The interview provides unique insight into the Company's latest corporate developments, updates on recently-achieved milestones, and current upcoming catalyst. Additionally, Mr. Corin provides his perspective on how Q BioMed Inc. is well positioned to build upon its current pipelines and creating continued shareholder value.
NEW YORK , Feb. 1, 2019 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today the Company's CEO Denis Corin will deliver a corporate presentation and conduct ...
NEW YORK, NY / ACCESSWIRE / January 28, 2019 / Shares of Q BioMed Inc. (QBIO) rose on heavy volume after the company announced that a new collaboration among researchers at McMaster University, Mannin Research and the emerging biotechnology accelerator, focuses on ophthalmic drug delivery and formulation experiments for MAN-01, a first in class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery. With 70 million patients in the world, and with expectations that this will grow to 100 million in the coming years, more effective and more easily delivered glaucoma treatments are needed by ophthalmologists and patients.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, announced today that its technology partner, Mannin Research, has initiated a collaboration with McMaster University of Ontario, Canada. The collaboration is focused on ophthalmic drug delivery and formulation experiments for MAN-01, a first-in-class small molecule to treat Primary Open-Angle Glaucoma. Experiments will be conducted Dr. Heather Sheardown, a world renowned thought leader in ophthalmic biomaterials and drug delivery.
LOS ANGELES, CA / ACCESSWIRE / January 18, 2019 / A new report indicates that an anticipated key FDA decision is set to transform Q BioMed (QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. When Corin was asked to acknowledge the "buzz" surrounding upcoming catalysts, he stated: "A lot of the focus over the last year or so has been on the Strontium Chloride Sr-89 Injection or Metastron™ assets because its close to commercialization and I guess the first real commercial catalyst is that we're waiting for FDA approval of the manufacturing facility in South Texas.
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, announced today that Pamela Ventola Phd, from Yale University has joined its Advisory Committee for its QBM-001 clinical program. QBM-001 is being developed and tested for the treatment of minimally verbal or non-verbal toddlers with an Autism Spectrum Disorder (ASD).
SmallCapVoice.com, Inc. (SCV) and Q BioMed Inc. (QBIO) (the "Company"), a commercial stage biotechnology company, announced today that a new audio interview with the Company is now available. Denis Corin, CEO of Q BioMed Inc., called in to SmallCapvoice.com to go over the innovative biotechnology firm’s business model, including a discussion about a key pending FDA catalyst which is set to help transform the company into a revenue generating biotech. Corin also dissects the importance of Q BioMed’s acquisition of Cancer Pain Drug Metastron™ from GE Healthcare and goes over the markets they aim to serve with their innovative products and formulations in various other indications.
Q BioMed Inc. (QBIO), a commercial stage biotechnology company provides the following update to its shareholders and interested investors. It's been proven safe and effective over many years of use.
Q BioMed Inc. (OTCQB: QBIO), a biotechnology acceleration company, is pleased to announce a collaborative agreement with SRI International to provide formulation development, preclinical development, and early clinical manufacturing of QBM-001, in support of Q BioMed's Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. SRI has broad expertise in solving formulation, drug delivery, and characterization challenges of small molecule drugs and biologics.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that it has entered into agreement to acquire the metastatic skeletal cancer palliation drug, Metastron™, from GE Healthcare. The agreement gives Q BioMed ownership of the brand, trademarks and market authorizations in 22 countries. In addition, all historical and current sales and distribution data related to those market authorisations will be assigned or transferred to Q BioMed to allow for as seamless a transition as possible in all markets.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to announce that Robert Derham, a member of the Q BioMed team and founder of CheckOrphan and architect of the world's first access program database, hosted a roundtable discussion on how companies can compliantly communicate their expanded access program and participated on a panel discussion about how to more effectively work with patients and patient organizations when executing an expanded access program. Expanded access programs are highly regulated programs that provide people with medicine that has not yet been approved on the market.
Q BioMed Inc. (QBIO), a biotechnology acceleration company, is pleased to provide an update on QBM001, its Autistic Spectrum Disorder (ASD) drug development program for non-verbal or minimally verbal autistic children. Q BioMed continues to develop its intellectual property including its patent pending QBM-001 drug technology, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders.